Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases (scientific article published on 13 October 2009)

Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta

Q30319511

Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells

Q30319950

Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions

Q30320504

The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease

Q30432239

Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model

Q30478167

Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model

Q30489966

Alzheimer disease models and human neuropathology: similarities and differences

Q30499574

Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain

Q31853679

Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques

Q33221293

High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain

Q33258748

Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline

Q33895797

Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels

Q33931836

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

Q34452028

Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets

Q34784378

Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models

Q35070000

Subcellular topography of neuronal Abeta peptide in APPxPS1 transgenic mice

Q35103335

Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration

Q35683326

Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology

Q35747757

Full-length amyloid-beta (1-42(43)) and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques.

Q35782745

Intraneuronal Abeta42 accumulation in human brain.

Q35793325

A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide--the first step of a fatal cascade

Q35918740

Amyloid beta-peptide: the inside story

Q36173152

Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity

Q39839629

Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide

Q39888501

Isolation and partial characterization of neurofibrillary tangles and amyloid plaque core in Alzheimer's disease: immunohistological studies

Q43505015

Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains

Q43517947

Pyroglutamate-modified amyloid beta-peptides--AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival

Q44158602

Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice

Q44182586

Consistent immunohistochemical detection of intracellular beta-amyloid42 in pyramidal neurons of Alzheimer's disease entorhinal cortex

Q44214690

APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy

Q44346463

Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro

Q46109204

Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology

Q46330873

Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography

Q46956780

Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease

Q47208290

Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain.

Q47798328

Irreversible dimerization/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease

Q47962016

Association of a presenilin 1 S170F mutation with a novel Alzheimer disease molecular phenotype

Q48168301

Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease

Q48314104

Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains

Q48344258

Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation.

Q48404445

Age-dependent axonal degeneration in an Alzheimer mouse model.

Q48424439

Mass spectrometry of purified amyloid beta protein in Alzheimer's disease

Q48443925

N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits

Q48463843

Intraneuronal APP/A beta trafficking and plaque formation in beta-amyloid precursor protein and presenilin-1 transgenic mice.

Q48529379

Age, neuropathology, and dementia

Q48597534

Hippocampal A beta 42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice

Q48633176

Isolation, chemical characterization, and quantitation of A beta 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits

Q48638383

Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains

Q48682997

Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP/PS1KI mice

Q48855353

Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain

Q48917681

Behavioral changes in transgenic mice expressing both amyloid precursor protein and presenilin-1 mutations: lack of association with amyloid deposits.

Q52173404

Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques.

Q53203663

APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques.

Q53246100

Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.

Q53264641

beta-amyloid is different in normal aging and in Alzheimer disease.

Q53271609

Intracellular Aß triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer's disease.

Q53296770

The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities in vitro than full-length A beta.

Q53336810

Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain

Q73067058

The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain

Q74290658

On the seeding and oligomerization of pGlu-amyloid peptides (in vitro)

Q79212522

Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease

Q84588034

P4510

describes a project that uses

ImageJ

Q1659584

P433

issue

P921

main subject

pathology

Q7208

Alzheimer's disease

Q11081

P304

page(s)

85-96

P577

publication date

2009-10-13

P1433

published in

Journal of Neural Transmission

Q15750921

P1476

title

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases

P478

volume

117

Reverse relations

cites work (P2860)

Q55021292	A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.
Q53311356	Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models.
Q36605288	Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias
Q35161238	Age-related changes of neuron numbers in the frontal cortex of a transgenic mouse model of Alzheimer's disease
Q36340365	Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X.
Q33786789	Alzheimer's Aβ peptides with disease-associated N-terminal modifications: influence of isomerisation, truncation and mutation on Cu2+ coordination
Q35743990	Alzheimer's Disease-Related Protein Expression in the Retina of Octodon degus
Q30316057	An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice
Q34348316	Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: Relevance for immunotherapy
Q28744420	Aβ peptide fibrillar architectures controlled by conformational constraints of the monomer
Q46335422	Aβ truncated species: Implications for brain clearance mechanisms and amyloid plaque deposition
Q38016898	Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease
Q60492861	Cu(II) binding to various forms of amyloid-β peptides. Are they friends or foes?
Q35005432	Development of a new DNA vaccine for Alzheimer disease targeting a wide range of aβ species and amyloidogenic peptides
Q33942884	Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease
Q27332086	Endothelial LRP1 transports amyloid-β(1-42) across the blood-brain barrier
Q48562250	Expression of the Alzheimer's Disease Mutations AβPP695sw and PSEN1M146I in Double-Transgenic Göttingen Minipigs
Q33624303	Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease
Q50690253	Gene Expression Profiling in the APP/PS1KI Mouse Model of Familial Alzheimer's Disease.
Q34995785	Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms
Q30497751	Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis
Q35246412	Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease
Q35679473	Mitochondrial dysfunction induced by a post-translationally modified amyloid linked to a familial mutation in an alternative model of neurodegeneration
Q37485472	N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody
Q42278922	N-truncated Aβ4-x peptides in sporadic Alzheimer's disease cases and transgenic Alzheimer mouse models
Q37043304	N-truncated amyloid β (Aβ) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits
Q38118901	Neurotoxic saboteurs: straws that break the hippo's (hippocampus) back drive cognitive impairment and Alzheimer's Disease
Q34575806	Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice
Q36984142	Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study
Q27437619	Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease
Q94503720	Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology
Q30512697	Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease
Q35604177	Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease
Q37062829	Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models
Q35660682	Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core
Q38176899	Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
Q36356545	Pyroglutamate-Modified Amyloid-β(3-42) Shows α-Helical Intermediates before Amyloid Formation
Q64095768	Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1-40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology
Q48912014	Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Aβ is induced by pyroglutamate-Aβ formation.
Q46902534	Structural analysis of the pyroglutamate-modified isoform of the Alzheimer's disease-related amyloid-β using NMR spectroscopy
Q46348872	Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy
Q34792043	Targets for AD treatment: conflicting messages from γ-secretase inhibitors
Q34481815	The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ
Q89052844	Unveiling Brain Aβ Heterogeneity Through Targeted Proteomic Analysis
Q37322106	pGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity